Search results
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Zacks via Yahoo Finance· 1 month agoAstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra...
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 4 weeks agoAstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically...
AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong
Zacks via Yahoo Finance· 8 months agoAstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving...
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
Zacks via Yahoo Finance· 10 months agoAstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not...
AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down
Zacks via Yahoo Finance· 3 months agoAstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects...
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
Zacks via Yahoo Finance· 1 year agoAstraZeneca’s AZN first-quarter 2023 core earnings of 96 cents per American depositary share (ADS)...
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
Zacks via Yahoo Finance· 6 months agoAstraZeneca’s AZN third-quarter 2023 core earnings of 87 cents per American depositary share (ADS)...
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Zacks via Yahoo Finance· 3 days agoAstraZeneca AZN announced its long-term plan to generate $80 billion in total revenues by 2030,...
AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up
Zacks via Yahoo Finance· 2 years agoAstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises...